Clinical trials: Endometrial Cancer Recurrent
Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
This phase II trial studies how well sunitinib malate works in treating patients with endometrial cancer that has come back after a period of improvement (recurrent) or has spread to other places in the body (metastatic).
- Conditions
- Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT00478426
- Testing
- Sunitinib Malate
- Where
- 29 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Endometrial Cancer
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer
- Trial name
- NCT00003939
- Testing
- trabectedin
- Volunteers
- 132 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Carcinoma, TP53 Mutation
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial…
- Conditions
- Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
- Trial name
- NCT06413992
- Testing
- Fluzoparib, Camrelizumab, paclitaxel (albumin bound)
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Endometrial Carcinosarcoma
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma.
- Trial name
- NCT05156268
- Testing
- Pembrolizumab, Olaparib
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Carcinoma
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT01455493
- Testing
- GDC-0980
- Where
- 28 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Lynch Syndrome, Recurrent Endometrial Carcinoma
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent).
- Conditions
- Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma
- Trial name
- NCT04906382
- Testing
- Biopsy, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Floor Backes, MD
Endometrial Cancer
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine…
- Trial name
- NCT01367002
- Testing
- Carboplatin/Paclitaxel, Trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Endometrial Cancer
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Primary Objective: To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.
- Trial name
- NCT00388154
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030485
- Testing
- erlotinib hydrochloride
- Where
- 8 sites in Canada
- Sponsor
- National Cancer Institute (NCI)
Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
Endometrial Cancer Lymphadenectomy Trial
The primary aim of this trial is to ascertain whether or not systematic pelvic and para-aortic lymphadenectomy (LNE) does have a significant impact on overall survival (OS) in patients with endometrial cancer (EC) FIGO Stages I…
- Trial name
- ECLAT (NCT03438474)
- Testing
- Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE)
- Where
- 61 sites in Germany, Japan and 1 more
- Volunteers
- 640 people
- Sponsor
- Philipps University Marburg
Endometrial Cancer, Uterine Carcinosarcoma
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.
- Trial name
- EndoBARR (NCT03694262)
- Testing
- Rucaparib, Bevacizumab, Atezolizumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin